[go: up one dir, main page]

PE20181172A1 - Proceso mejorado para la preparacion de compuestos anfifilicos de imidazolinio - Google Patents

Proceso mejorado para la preparacion de compuestos anfifilicos de imidazolinio

Info

Publication number
PE20181172A1
PE20181172A1 PE2017002358A PE2017002358A PE20181172A1 PE 20181172 A1 PE20181172 A1 PE 20181172A1 PE 2017002358 A PE2017002358 A PE 2017002358A PE 2017002358 A PE2017002358 A PE 2017002358A PE 20181172 A1 PE20181172 A1 PE 20181172A1
Authority
PE
Peru
Prior art keywords
preparation
compounds
amphifilic
improved process
imidazolinium compounds
Prior art date
Application number
PE2017002358A
Other languages
English (en)
Inventor
Marco Brunjes
Mark James Ford
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of PE20181172A1 publication Critical patent/PE20181172A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referido a procesos para la preparacion de compuestos anfifilicos de imidazolinio, tales como cloruro de 1-[2-(9(Z)octadecenoiloxi)etil1]-2-(8(Z)-heptadecenil)-3-(2-hidroxietil)imidazolinio (DOTIM). En forma particular, da a conocer procesos para la sintesis de dichos compuestos que evitan la utilizacion de reactivos toxicos, poseen menor costo y generan menos desechos que los metodos convencionales. El DOTIM y los compuestos afines pueden formularse como liposomas cationicos que son utiles para su utilizacion como vectores quimicos para la administracion de acido nucleico en la terapia genica
PE2017002358A 2015-05-04 2016-05-03 Proceso mejorado para la preparacion de compuestos anfifilicos de imidazolinio PE20181172A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562156677P 2015-05-04 2015-05-04

Publications (1)

Publication Number Publication Date
PE20181172A1 true PE20181172A1 (es) 2018-07-20

Family

ID=55910251

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002358A PE20181172A1 (es) 2015-05-04 2016-05-03 Proceso mejorado para la preparacion de compuestos anfifilicos de imidazolinio

Country Status (23)

Country Link
US (1) US10479768B2 (es)
EP (1) EP3292106B1 (es)
JP (1) JP6843765B2 (es)
KR (1) KR102667024B1 (es)
CN (1) CN107801395B (es)
AR (1) AR104524A1 (es)
AU (2) AU2016256965A1 (es)
CA (1) CA2984696C (es)
CL (1) CL2017002775A1 (es)
CO (1) CO2017011326A2 (es)
EC (1) ECSP17073692A (es)
ES (1) ES2901788T3 (es)
HK (1) HK1252354A1 (es)
IL (1) IL255344B (es)
MX (1) MX393908B (es)
PE (1) PE20181172A1 (es)
PL (1) PL3292106T3 (es)
RU (1) RU2753541C2 (es)
TW (1) TWI714580B (es)
UA (1) UA123265C2 (es)
UY (1) UY36667A (es)
WO (1) WO2016177693A1 (es)
ZA (1) ZA201708190B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705655A (en) * 1992-12-17 1998-01-06 Megabios Corporation Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
US5830878A (en) 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US6121457A (en) * 1997-11-14 2000-09-19 Megabios Corporation Compositions and methods using novel substituted imidazolium lipids
GB0201165D0 (en) * 2002-01-18 2002-03-06 Unilever Plc Azetidinium modidfied poymers and fabric treatment composition
US7786153B2 (en) * 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
US8044215B2 (en) 2009-04-29 2011-10-25 Juvaris Biotherapeutics, Inc. Methods for the preparation of amphillic nitrogen containing imidazolinium derivative compounds

Also Published As

Publication number Publication date
JP6843765B2 (ja) 2021-03-17
CN107801395B (zh) 2022-02-22
UY36667A (es) 2016-06-30
AU2020256364A1 (en) 2020-11-12
CA2984696A1 (en) 2016-11-10
RU2753541C2 (ru) 2021-08-17
RU2017141979A3 (es) 2019-11-01
CO2017011326A2 (es) 2018-01-31
KR20170141738A (ko) 2017-12-26
AU2016256965A1 (en) 2017-11-23
TW201713627A (zh) 2017-04-16
TWI714580B (zh) 2021-01-01
EP3292106A1 (en) 2018-03-14
UA123265C2 (uk) 2021-03-10
MX2017014138A (es) 2018-03-15
US20180148415A1 (en) 2018-05-31
ECSP17073692A (es) 2017-12-01
EP3292106B1 (en) 2021-10-27
MX393908B (es) 2025-03-24
IL255344A0 (en) 2017-12-31
AU2020256364B2 (en) 2022-03-17
BR112017023742A2 (pt) 2018-07-31
KR102667024B1 (ko) 2024-05-17
JP2018515483A (ja) 2018-06-14
CN107801395A (zh) 2018-03-13
ZA201708190B (en) 2020-02-26
CL2017002775A1 (es) 2018-06-01
IL255344B (en) 2021-01-31
WO2016177693A1 (en) 2016-11-10
HK1252354A1 (zh) 2019-05-24
RU2017141979A (ru) 2019-06-04
PL3292106T3 (pl) 2022-02-14
AR104524A1 (es) 2017-07-26
CA2984696C (en) 2024-02-06
ES2901788T3 (es) 2022-03-23
US10479768B2 (en) 2019-11-19

Similar Documents

Publication Publication Date Title
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
CL2016002888A1 (es) Compuestos derivados de pirazolopiridinas y pirazolopirimidinas; composicion farmacéutica y su uso como inhibidores selectivos de janus quinasas (jak) en el tratamiento de enfermedades como congestion nasal, asma, epoc, rinitis alergica, diabetes entre otras.
EP2855369A4 (en) PROCESS FOR PROCESSING ORGANIC MATERIAL
CL2014002541A1 (es) Compuestos derivados de imidazol fusionado con heterociclos, como inhibidores de diacilglicerol aciltransferasa 2; composicion farmaceutica que los comprende, util para el tratamiento de diabetes tipo i y ii, enfermedad cardiaca coronaria, artritis, trombosis, alzheimer, entre otras enfermedades.
PH12014501029A1 (en) Pharmaceutical compositions comprising glitazones and nrf2 activators
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
GT201300123A (es) Sal(es) de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-(2,3-d)-pirimidin-6-carboxilico y procesos para su elaboracion
CO6660482A2 (es) N-[(het)]ariletil)pirazol](tio) carboximidas y sus análogos heterosustituidos
EP3368228A4 (en) HAND-HELD APPLICATOR FOR SOLID CHEMICALS
GB201711603D0 (en) Method for constructing nucleic acid molecule
EP3414255A4 (en) PREPARATIVE ELECTROPHORETIC PROCESS FOR THE TARGETED CLEANING OF GENOMIC DNA FRAGMENTS
BR112017008103A2 (pt) composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo.
EP2920187A4 (en) METHOD FOR THE USE OF BINUCLEAR GOLD (I) COMPOUNDS FOR CANCER TREATMENT
EP3277861A4 (en) METHOD FOR TREATING A LIQUID ELECTROLYTE SOLUTION
MX2015011156A (es) Procedimiento de fluoracion escalonado y sistema de reactores.
FR2993270B1 (fr) Procede de moussage chimique en presence de charges de renfort
IT201700068744A1 (it) Processo per la produzione di acido levulinico.
EP3369703A4 (en) HYDROGEN PRODUCTION PROCESS BACK
EP3441362A4 (en) METHOD FOR ADDING CHLORINE FLUORIDE
PE20181172A1 (es) Proceso mejorado para la preparacion de compuestos anfifilicos de imidazolinio
FR2970649B1 (fr) Procede de traitement cosmetique comprenant la formation in-situ d'une composition aerogel.
EP3359513A4 (en) PROCESS FOR PREPARING ORGANIC HALIDS
PT3145553T (pt) Arn de interferência pequeno (arnsi) para a terapêutica da osteopetrose autossómica dominante de tipo 2 (ado2) causada por mutação génica de clcn7 (ado2 dependente de clcn7)
BR112015001316A2 (pt) montagem de fragmento de dna de alta produção
FR2988088B1 (fr) Procede de traitement d'effluents de production d'un compose aromatique derive de benzene dihydroxyle.